

PATENTS Atty. Docket No. HYZ-069CN (47508.530)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Agrawal

Art Unit:

1635

Serial No.:

09/837,806

Examiner:

Zara, Jane J.

Filing Date:

April 18, 2001

Customer No.:

23483

Title:

**Novel HIV-Specific Synthetic** 

Oligonucleotides and Methods of

Their Use

Confirmation No.:

8489

## **CERTIFICATION UNDER 37 CFR § 1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail with sufficient postage in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Signature and of Mail Deposit

Stephanie R. Johnson

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant and their attorney are aware of the following publications and information listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. Please note, however, that reference A2, Remington's Pharmaceuticals Sciences (18<sup>th</sup> Ed.) is not enclosed as it is a book and too voluminous to provide with this Statement.

This submission does not represent that a search has been made and does not constitute an admission that the listed documents are material to patentability or that the listed documents are prior art. If it should be determined that any of the listed documents do not constitute "prior 04/16/2004 HGUTEMAI 00000006 080219 09837806

02 FC:1806

180.00 DA

Appl. No. 09/837,806 Filed. April 18, 2001

art" under United States law, Applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

This Supplemental Information Disclosure Statement is being filed after the mailing date of a first Office Action from the Patent and Trademark Office following a Request for Continued Examination for the above-referenced application on the merits. Therefore, the Commisioner is authorized to charge the \$180.00 fee, pursuant to 37 C.F.R. § 1.17(p), for the submission of the Information Disclosure Statement to our Deposit Account No. <u>08-0219</u>.

No other fees are believed to be due for this submission, however the Commissioner is hereby authorized to charge any fee deficiency or credit any overpayment to Deposit Account No. <u>08-0219</u>.

Respectfully submitted,

Date: April 13, 2004

Ann-Louise Kerner, Ph.D. Registration No. 33,523 Attorney for Applicant

Hale and Dorr LLP 60 State Street Boston, Massachusetts 02109

Tel: (617) 526-6192 Fax: (617) 526-5000

Subt. Form PTO-1449  E JONFORMATION DISCLOSURE	Docket Number HYZ-069CN (47508-530)	Application Number 09/837,806		
IN AN APPLICATION (Use several sheets if necessary)	Applicant Agrawal			
	Filing Date	Group Art Unit		
1 OF 1	4/18/2001	1635		

		U.S	S. Patent Docume	nts		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,652,355	7/29/1997	Metelev, et al.			
	5,652,356	7/29/1997	Agrawal			
	5,801,154	9/1/1998	Baracchini, et al.			
	6,608,035	8/19/2003	Agrawal, et al.			
	6,645,943	11/11/2003	Agrawal, et al.			

Foreign Patent Documents							
EXAMINER DOCUMENT	DOCUMENT		COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL	NUMBER	DATE	COUNTRY	CLASS		YES	NO
					<del>-</del>		
					<del> </del>		
		·					

		Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)			
	A1	Furdon (1989) "RNase II cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds," <i>Nucleic Acids Research</i> , Vol. 17(22): 9193-9205			
	A2	Gennaro (ed.) (1990) Remington's Pharmaceutical Sciences (18 <sup>th</sup> Ed.) Mack Publishing Co., Easton, PA			
	<del>                                     </del>				
	<b></b>				
	<del></del>				
<del></del>	$\vdash$				
	$\vdash$				
	<del>                                     </del>				
	<del>                                     </del>				
-	<del> </del>				

**EXAMINER:** Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

DATE CONSIDERED

**EXAMINER**